Results 181 to 190 of about 10,206 (212)

Clinical Pharmacokinetics of Salmeterol

Clinical Pharmacokinetics, 2012
Mario Cazzola
exaly  

Antiinflammatory Effects of Salmeterol after Inhalation of Lipopolysaccharide by Healthy Volunteers

American Journal of Respiratory and Critical Care Medicine, 2005
C Arnold Spek, Jaring S Van Der Zee
exaly  

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial

Lancet Respiratory Medicine,the, 2014
Klaus F Rabe, Leonardo M Fabbri, Elliot Israel   +2 more
exaly  

Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes

COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009
Antonio Anzueto, Gary T Ferguson
exaly  

Salmeterol rash

The Lancet, 1991
MatthewQ.F. Hatton, MartinB. Allen, ElizabethJ. Mellor, NigelJ. Cooke   +3 more
openaire   +1 more source

Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy

Thorax, 2010
Mark Weatherall
exaly  

Salmeterol xinafoate in children

Medical Journal of Australia, 1995
C F, Robertson, C, Mellis, R, Staugas, A F, Isles, L I, Landau   +4 more
openaire   +2 more sources

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

Chest, 2006
Denis E O'donnell, Frank C Sciurba, Bartolome Celli   +2 more
exaly  

Salbutamol/salmeterol

Reactions Weekly, 2018
openaire   +1 more source

Systemic administration of β 2 -adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses

British Journal of Pharmacology, 2006
James G Ryall, Martin N Sillence, Gordon S Lynch   +2 more
exaly